Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $10.15. Don't Miss ...

Morgan Stanley has recently resumed Regenxbio Inc (RGNX) stock to Overweight rating, as announced on November 15, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed the ...

This is the online version of STAT's email newsletter Health Care Inc, delivered to your inbox every Monday. Sign up here. ...

Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...

The agency's openness to a targeted pivotal study shows it’s still willing to consider accelerated clearance for Duchenne ...

REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.